Featured Research

from universities, journals, and other organizations

Safety Problems For Biological Products Documented

Date:
October 23, 2008
Source:
JAMA and Archives Journals
Summary:
Approximately one in four biological medicinal products (such as antibodies, enzymes and insulin) approved since 1995 in the US and Europe have had at least one safety-related regulatory action issued for them 10 years after their approval, including about 11 percent receiving a "black box" warning, according to a new study.

Approximately one in four biological medicinal products (such as antibodies, enzymes and insulin) approved since 1995 in the U.S. and Europe have had at least one safety-related regulatory action issued for them 10 years after their approval, including about 11 percent receiving a "black box" warning, according to a study in the October 22/29 issue of JAMA, a theme issue on the Health of the Nation.

Related Articles


Biologicals are preparations in which the active substance is produced by or extracted from a biological source, such as antibodies, enzymes and hormones. They represent an important and growing part of medical therapies, with more than 250 biologicals having been approved since 1982, according to background information in the article. "Between 2003 and 2006, biologicals represented 24 percent and 22 percent of all new chemical entities approved by the U.S. and EU [European Union] regulatory authorities, respectively," the authors write. "Biologicals are a relatively new class of medicines that carry specific risks (e.g., immunogenicity [the ability to stimulate an immune response]). However, limited information is available on the nature and timing of safety problems with their use that were identified after approval."

Thijs J. Giezen, Pharm.D., of Utrecht University, Utrecht, the Netherlands, and colleagues examined the nature and probability of safety-related regulatory actions issued for biologicals approved in the United States and/or the European Union between January 1995 and June 2007. Vaccines, allergenic products (a substance capable of causing an allergic reaction), and products for further manufacture and transfusion purposes were excluded.

A total of 174 biological medicinal products obtained approval during the study period, including 136 biologicals approved in the U.S. and 105 in the European Union, of which 67 biologicals obtained approval in both regions during this time. The researchers found that between January 1995 and June 2008, 82 safety-related regulatory actions were issued for 41 of the 174 biologicals (23.6 percent). These included 46 written communications (warnings of health hazards) to health care professionals in the U.S., 17 in the European Union, and 19 black box warnings (warning of serious health hazards). No biologicals were withdrawn due to safety reasons.

The average time to a safety-related regulatory action was 3.7 years and 70.7 percent of the safety-related regulatory actions were issued within five years after approval. The probability of a biological requiring its first safety-related regulatory action was 14 percent three years after approval and 29 percent ten years after approval. Biologicals that were the first to be approved in their chemical, pharmacological, and therapeutic subgroup had a significantly higher risk for the occurrence of its first safety-related regulatory action compared with later approved products.

The safety-related regulatory actions issued for biologicals mostly involved the system organ classes of general disorders and administration site conditions (26.8 percent of 82), infections and infestations (22 percent), immune system disorders (15.9 percent), and neoplasms benign, malignant, and unspecified (12.2 percent). "The safety-related regulatory actions issued in the system organ class of general disorders and administration site conditions can be partly explained by the infusion reactions occurring after the parenteral [intravenously or by injection] route of administration, which is the mode of administration for most biologicals. A more in-depth evaluation of the mode of action of biologicals might have predicted some safety problems during the developmental phase."

"Although the limitations of preclinical trials for biologicals are acknowledged, results from pharmacology studies, preclinical studies, and clinical studies might result in the prediction of potential risks related to the drug for which close monitoring is needed in the postapproval setting. Health care professionals should be aware of the specific risks related to the relatively new class of biologicals to be able to provide a link between the use of the biological and the patient presenting with a clinical problem," the authors write.

Editorial: Prescription Drugs, Products Liability, and Preemption of Tort Litigation

In an accompanying editorial, Catherine D. DeAngelis, M.D., M.P.H., Editor-in-Chief, JAMA, and Phil B. Fontanarosa, M.D., M.B.A., Executive Deputy Editor, JAMA, Chicago, write that these findings show the need for improvement in the drug approval process and the postmarketing surveillance system.

"As shown in the study by Giezen et al, many safety problems are identified only after drug approval. The human body is in a constant state of change and the effects of some drugs will manifest only after exposure over time. Furthermore, some serious adverse drug effects are quite uncommon and require use of the drug in large numbers of patients to become evident. The safety of drugs in a clinical trial, the study type used for Food and Drug Administration approval, is based on specific participant types, numbers, and design that cannot ensure the true safety of a drug. In addition, manipulation of study results by the drug manufacturers (who almost always sponsor studies used for decisions about drug approval) can obscure the true safety profile of a drug."

"Given the current imperfect process for approval and the flawed postmarketing surveillance system, the drug and device regulation process is at best an inexact and incomplete science. Until these deficiencies in the system are remedied, some patients inevitably will continue to experience harm from the use of newly marketed products as well as from use of other approved medications. Just as with other consumer products that cause harms, consumers (i.e., patients) who are injured by defective medical devices or by pharmaceutical products with inadequate warnings of potential harms may have to resort to legal action as recourse for their injuries."


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal Reference:

  1. Giezen et al. Safety-Related Regulatory Actions for Biologicals Approved in the United States and the European Union. JAMA The Journal of the American Medical Association, 2008; 300 (16): 1887 [link]

Cite This Page:

JAMA and Archives Journals. "Safety Problems For Biological Products Documented." ScienceDaily. ScienceDaily, 23 October 2008. <www.sciencedaily.com/releases/2008/10/081021120743.htm>.
JAMA and Archives Journals. (2008, October 23). Safety Problems For Biological Products Documented. ScienceDaily. Retrieved December 18, 2014 from www.sciencedaily.com/releases/2008/10/081021120743.htm
JAMA and Archives Journals. "Safety Problems For Biological Products Documented." ScienceDaily. www.sciencedaily.com/releases/2008/10/081021120743.htm (accessed December 18, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, December 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Kids Die While Under Protective Services

Kids Die While Under Protective Services

AP (Dec. 18, 2014) As part of a six-month investigation of child maltreatment deaths, the AP found that hundreds of deaths from horrific abuse and neglect could have been prevented. AP's Haven Daley reports. (Dec. 18) Video provided by AP
Powered by NewsLook.com
UN: Up to One Million Facing Hunger in Ebola-Hit Countries

UN: Up to One Million Facing Hunger in Ebola-Hit Countries

AFP (Dec. 17, 2014) Border closures, quarantines and crop losses in West African nations battling the Ebola virus could lead to as many as one million people going hungry, UN food agencies said on Wednesday. Duration: 00:52 Video provided by AFP
Powered by NewsLook.com
When You Lose Weight, This Is Where The Fat Goes

When You Lose Weight, This Is Where The Fat Goes

Newsy (Dec. 17, 2014) Can fat disappear into thin air? New research finds that during weight loss, over 80 percent of a person's fat molecules escape through the lungs. Video provided by Newsy
Powered by NewsLook.com
Why Your Boss Should Let You Sleep In

Why Your Boss Should Let You Sleep In

Newsy (Dec. 17, 2014) According to research out of the University of Pennsylvania, waking up for work is the biggest factor that causes Americans to lose sleep. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins